*Affiliations of authors: B.S. Reichman, Strang-Cornell Breast Center, Strang Cancer Prevention Center, New York, N.Y., Department of medicine, The New York Hospital-Cornell Medical Center, and Cornell University Medical Collage. K.B. Green, Department of Hematology/Oncology, New York Hospital-Cornell Medical Center. Correspondence to: Bonnie S. Reichman, M.D., Strang-Cornell Breast Center, 428 E. 72nd St., New York, NY 10021.

1.Damewood MD, Grochow LB: Prospects for fertility after chemotherapy or radiation for neoplastic disease. fertil Steril 45:443-459, 1986

2.Chapman RM, Sutcliffe SB, Malpas JS: Cytotoxic-induced ovarian failure in women with Hodgkin's disease. JAMA 242: 1877 -1881, 1979

3.Flood JT. Hodgen GD: The physiology of fertilization, implantation, and early human development. IN Danforth's Obstetrics and Gynecology, Sixth Edition (Scott JR. DiSaia PJ, Hammond CB, et al, eds). Philadelphia: Lippincott, 1990, pp 75-77

4.Coulam CB: Neuroendocrinology and ovarian function. IN Danforth's Obstetrics and Gynecology, Sixth Edition (Scott JR. DiSaia PJ, Hammond CB, et al, eds). Philadelphia: Lippincott, 1990, pp 57-73

5.Horning SJ, Hope RAT, Kaplan HS, et al: Female reproductive potential after treatment for Hodgkin's disease. N Engl J Med 304:1377-1382, 1981

6.Warne GL, Fairly KF, Hobbs JB, et al: Cyclophosphamide-induced ovarian failure. N Engl J Med 289:1159-1162, 1973

7.Koyama H. Wada T, Nishizawa Y, et al: Cyclophosphamide-induced ovarian failure and its therapeutic significance in patients with breast cancer. Cancer 39:1403-1409, 1977

8.Gradishar WJ, schilsky RL: Ovarian function following radiation and chemotherapy for cancer. Semin Oncol 16:425-436, 1989

9.Santoro A. Bonadonna G. Valagussa P, et al: Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. J Clin Oncol 5:27-37, 1987

10.Rose DP. Davis TE: Ovarian function in patients receiving adjuvant chemotherapy for breast cancer. Lancet 1:1174-1176, 1977

11.Samaan NA, DeAsis DN, Buzdar AU, et al: Pituitary-ovarian function in breast cancer patients on adjuvant chemoimmunotherapy. Cancer 41:2084-2087, 1978

12.Murugasan K, Rao SVS, Vij U, et al: Effect of chemotherapy on gonadal function in women with breast cancer. Indian J Med Res 87:42-45, 1988

13.Dowsett M, Richner J: Effects of cytotoxic chemotherapy on ovarian and adrenal steroidogenesis in pre-menopausal breast cancer patients. Oncology 48:215-220, 1991

14.Dnistrian AM, Schwartz MK, Fracchia AA, et al: Endocrine consequences of CMF adjuvant therapy in premenopausal and postmenopausal breast cancer patients. Cancer 51:803-807, 1983

15.Bonadonna G, Valgussa P: Adjuvant systemic therapy for resectable breast cancer. J Clin Oncol 3:259-275, 1985

16.Forbes JF: Long-term effects of adjuvant chemotherapy in breast cancer. Acta Oncol 31:243-250, 1992

17.Sutton R, Buzdar AU, Hortobagyi GN: Pregnancy and offspring after adjuvant chemotherapy in breast cancer patients. CAncer 65:874-850, 1990

18.Gallenberg MM, loprinzi CL: Breast cancer and pregnancy. Semin Oncol 16:369-376, 1989

19.Petrek JA, Dukoff R, Rogatko A: Prognosis of pregnancy-associated breast cancer. Cancer 67:869-972, 1991

20.Petrek JA: Breast cancer and pregnancy. In Breast Diseases, 2nd Edition (Harris JR, Hellman S, Henderson IC, et al, eds). Philadelphia: Lippincott, 1991, pp 809-816

21.Nugent P, O'Connell TX: Breast cancer and pregnancy. Arch Surg 120:1221-1224, 1985

22.Ribeiro G. Jones DA, Jones M: Carcinoma of the breast associated with pregnancy. Br J Surg 73:607-609, 1986

23.Mignot L, Morvan F, sarrazin D, et al: Breast carcinoma and subsequent pregnancy. Proc ASCO 5:51, 1986

24.Doll DC, Ringenberg QS, Yarbro JW: Antineoplastic agents and pregnancy. Semin Oncol 16:337-346, 1989

25.Garber JE: Long-term follow-up of children exposed in utero to antineoplastic agents. semin oncol 16:437-444, 1989

26.Barber HRK: fetal and neonatal effects of cytotoxic agents. Obstet Gynecol 58:41s-47s, 1981

27.Sutcliffe SB: Treatment of neoplastic disease during pregnancy: maternal and fetal effects. Clin Invest Med 8:333-338, 1985

28.Redmond GP: Physiological changes during pregnancy and their implications for pharmacological treatment. Clin Invest Med 8:317-322, 1985

29.Kalter H, Warkany J: Congenital malformations. N Engl J Med 308:424-431, 1983

30.Turchi JJ, Villasis C: Anthracylines in the treatment of malignancy in pregnancy. Cancer 61:435-440, 1988

31.Mulvihill JJ, McKeen EA, Rosner F, et al: Pregnancy outcome in cancer patients. Cancer 60:1143-1150, 1987

32.Early Breast Cancer Trialists' Collaborative Group:systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 339:1-15, 71-85, 1992

33.Williamson K, Robertson FR, Ellis O, et al: Effect of LHRH agonist, Zoladex, on ovarian histology. Br J Surg: 75:595-596, 1988

34.Montz FJ, Wolff AJ, Gambone JC: Gonadal protection and fecundity rates in cyclophosphamide-treated rats. Cancer Res 51:2124-2126, 1991